Epoetin Alfa
-
Subject Areas on Research
- A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
- A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.
- Anaemia of CKD--the CHOIR study revisited.
- Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.
- Bloodless Orthotopic Heart Transplantation in a Jehovah's Witness.
- Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
- Correction of anemia with epoetin alfa in chronic kidney disease.
- DRIVE it home: making the case for prospective economic data collection in randomized clinical trials.
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
- Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.
- Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
- Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.
- Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
- Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
- Erythropoietin receptor contributes to melanoma cell survival in vivo.
- Erythropoietin: high profile, high scrutiny.
- Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
- Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy.
- Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
- Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
- Myelodysplastic syndromes.
- Normalization of hematocrit in hemodialysis patients does not affect silent ischemia.
- Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
- Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
- Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.
- Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
- Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
- Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).